Kyprolis
Biological
Amgen Inc.
Total Payments
$372.3M
Transactions
45,844
Doctors
9,277
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $26.4M | 589 | 183 |
| 2023 | $40.1M | 3,103 | 1,958 |
| 2022 | $13.6M | 7,790 | 3,707 |
| 2021 | $47.7M | 6,150 | 2,745 |
| 2020 | $43.4M | 4,243 | 1,831 |
| 2019 | $63.9M | 7,558 | 2,807 |
| 2018 | $65.8M | 8,452 | 3,042 |
| 2017 | $71.4M | 7,959 | 2,854 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $363.1M | 2,479 | 97.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5.3M | 2,537 | 1.4% |
| Consulting Fee | $1.6M | 473 | 0.4% |
| Travel and Lodging | $1.1M | 2,592 | 0.3% |
| Food and Beverage | $938,842 | 37,535 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $245,207 | 157 | 0.1% |
| Education | $483.02 | 71 | 0.0% |
Payments by Type
Research
$363.1M
2,479 transactions
General
$9.2M
43,365 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| [ECOG] Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Mul | Amgen Inc. | $55.3M | 0 |
| A Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Standard of Care to Determine MRD Negativity in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE) | Amgen Inc. | $31.7M | 0 |
| P3 Kd v KdD in Relapsed/Refractory MM (CANDOR) | Amgen Inc. | $21.9M | 3 |
| Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Patients with High Risk Smoldering Multiple Myeloma (A Black Swan Research Initiative cure bas | Amgen Inc. | $16.8M | 0 |
| A Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Standard of Care to Determine MRD Negativity in Patients with Newly-Diagnosed Multiple Myeloma ADVANCE | Amgen Inc. | $15.1M | 0 |
| Open-label, Single-arm, Phase 2 Study of Initial Treatment with Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy | Amgen Inc. | $13.3M | 0 |
| CFZ013 Weekly | Amgen Inc. | $12.3M | 1 |
| A Phase II Study of once weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma | Amgen Inc. | $10.5M | 0 |
| A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma | Amgen Inc. | $9.7M | 0 |
| A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination with Carfilzomib, High-dose Carfilzomib and Dexamethasone, and Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myel | Amgen Inc. | $9.3M | 0 |
| Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma | Amgen Inc. | $8.9M | 0 |
| A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | Amgen Inc. | $8.5M | 0 |
| [PARENT IST is IST-CAR-517] Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: a Clinical and Correlative Dose Escalation Study | Amgen Inc. | $8.5M | 0 |
| [SCRI Alliance] A Phase II Study of Carfilzomib for the Treatment of Patients with Advanced Neuroendocrine Cancers | Amgen Inc. | $8.1M | 0 |
| Open-label, Single-arm, Phase 2 Study of Initial Treatment with Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy | Amgen Inc. | $7.2M | 0 |
| Maintenance therapy with carfilzomib, pomalidomide and dexamethasone (CPd) in high-risk myeloma patients: A Phase 2 study with a safety run-in | Amgen Inc. | $7.2M | 0 |
| MONOCLONAL ANTIBODY-BASED SEQUENTIAL THERAPY FOR DEEP REMISSION IN MULTIPLE MYELOMA MASTER TRIAL | Amgen Inc. | $6.9M | 0 |
| (NCI) Carfilzomib, Lenalidomide, and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study | Amgen Inc. | $6.9M | 0 |
| Phase 2 Trial of Intensive daratumumab/carfilzomib based Chemo-immunotherapy for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation. The 2nd Chance Protocol | Amgen Inc. | $5.2M | 0 |
| Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study | Amgen Inc. | $4.9M | 0 |
Top Doctors Receiving Payments for Kyprolis — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | New York, NY | $74,185 | 60 |
| , M. D | Medical Oncology | Houston, TX | $73,966 | 129 |
| , M.D | Specialist | Carrollton, GA | $70,451 | 71 |
| , M.D | Hematology & Oncology | Albany, NY | $68,761 | 60 |
| , MD | Internal Medicine | Duarte, CA | $67,577 | 73 |
| , M.D | Hematology & Oncology | New York, NY | $66,590 | 71 |
| , M.D | Hematology | Hackensack, NJ | $65,692 | 81 |
| , MD | Hematology & Oncology | Moreno Valley, CA | $65,472 | 74 |
| , M.D | Hematology | Chardon, OH | $63,974 | 72 |
| , MD | Hematology & Oncology | Charleston, SC | $63,433 | 87 |
| , M.D | Internal Medicine | Mechanicsville, VA | $63,041 | 69 |
| , M.D | Medical Oncology | Fullerton, CA | $59,637 | 91 |
| , M.D | Hematology & Oncology | Birmingham, AL | $59,317 | 80 |
| , MD | Specialist | Norfolk, VA | $59,028 | 92 |
| Andrzej Jakubowiak | Medical Oncology | Chicago, IL | $57,546 | 37 |
| , M.D | Medical Oncology | Memphis, TN | $56,312 | 46 |
| , MD | Hematology & Oncology | Hiram, GA | $55,778 | 82 |
| Ariel Grajales Cruz | Hematology & Oncology | Tampa, FL | $55,637 | 37 |
| , MD | Hematology & Oncology | New Orleans, LA | $55,107 | 56 |
| , M.D | Hematology | Cleveland, OH | $55,042 | 66 |
| , M.D | Internal Medicine | Chicago, IL | $54,867 | 81 |
| , M.D | Hematology | Philadelphia, PA | $52,113 | 57 |
| , MD | Hematology & Oncology | Indianapolis, IN | $51,852 | 61 |
| , MD, MSC | Hematology & Oncology | New York, NY | $51,440 | 43 |
| , MD | Internal Medicine | Boston, MA | $50,742 | 24 |
Ad
Manufacturing Companies
- Amgen Inc. $372.3M
Product Information
- Type Biological
- Total Payments $372.3M
- Total Doctors 9,277
- Transactions 45,844
About Kyprolis
Kyprolis is a biological associated with $372.3M in payments to 9,277 healthcare providers, recorded across 45,844 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $26.4M was paid across 589 transactions to 183 doctors.
The most common payment nature for Kyprolis is "Unspecified" ($363.1M, 97.5% of total).
Kyprolis is associated with 20 research studies, including "[ECOG] Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Mul" ($55.3M).